Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Astria Therapeutics (Nasdaq: ATXS), a biopharmaceutical company focused on allergic and immunological diseases, has granted stock options to two new employees under its 2022 Inducement Stock Incentive Plan. The options, totaling 29,150 shares of common stock, were awarded on August 1, 2024, with an exercise price of $11.19 per share, matching the closing price on the grant date.
These options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over the following 36 months, contingent on continued employment. This grant aligns with Nasdaq Listing Rule 5635(c)(4) for inducement awards to new employees.
Astria Therapeutics (Nasdaq: ATXS), una società biofarmaceutica focalizzata sulle malattie allergiche e immunologiche, ha concesso opzioni su azioni a due nuovi dipendenti secondo il suo Piano di Incentivazione da Induzione del 2022. Le opzioni, per un totale di 29.150 azioni ordinarie, sono state assegnate il 1 agosto 2024, con un prezzo di esercizio di $11,19 per azione, corrispondente al prezzo di chiusura nella data di assegnazione.
Queste opzioni matureranno in quattro anni, con il 25% che matura dopo un anno e il resto che matura mensilmente nei successivi 36 mesi, a condizione di continuare l'impiego. Questa concessione è conforme alla Regola di Quotazione Nasdaq 5635(c)(4) per le assegnazioni di indizione ai nuovi dipendenti.
Astria Therapeutics (Nasdaq: ATXS), una compañía biofarmacéutica enfocada en enfermedades alérgicas e inmunológicas, ha otorgado opciones sobre acciones a dos nuevos empleados bajo su Plan de Incentivo por Inducción de 2022. Las opciones, que totalizan 29,150 acciones comunes, fueron otorgadas el 1 de agosto de 2024, con un precio de ejercicio de $11.19 por acción, coincidiendo con el precio de cierre en la fecha de otorgamiento.
Estas opciones se adquirirán en un periodo de cuatro años, con el 25% adquiriéndose después de un año y el resto adquiriéndose mensualmente durante los siguientes 36 meses, condicionado a la continuidad del empleo. Este otorgamiento está alineado con la Regla de Cotización Nasdaq 5635(c)(4) para los premios de inducción a nuevos empleados.
Astria Therapeutics (Nasdaq: ATXS)는 알레르기 및 면역 질환에 중점을 둔 생명공학 회사로, 2022 유도 주식 인센티브 계획에 따라 두 명의 새로운 직원에게 주식 옵션을 부여했습니다. 이 옵션의 총합은 29,150주의 보통주이며, 2024년 8월 1일에 부여되었고, 주당 $11.19의 행사 가격은 부여일의 종가와 일치합니다.
이 옵션은 4년에 걸쳐 분할 지급됩니다, 1년 후에 25%가 지급되고 나머지는 다음 36개월 동안 매월 지급되며, 지속적인 고용이 조건입니다. 이 부여는 새로운 직원에 대한 유도 상에 대한 나스닥 상장 규칙 5635(c)(4)와 일치합니다.
Astria Therapeutics (Nasdaq: ATXS), une entreprise bio-pharmaceutique axée sur les maladies allergiques et immunologiques, a accordé options sur actions à deux nouveaux employés dans le cadre de son Plan d'Incitation à l'Inducement de 2022. Les options, totalisant 29 150 actions ordinaires, ont été attribuées le 1er août 2024, avec un prix d'exercice de $11,19 par action, correspondant au prix de clôture à la date d'attribution.
Ces options s'acquitteront sur quatre ans, avec 25 % d'acquisition après un an et le reste s'acquittant mensuellement au cours des 36 mois suivants, sous réserve de la poursuite de l'emploi. Cette attribution est conforme à la Règle d'Inscription Nasdaq 5635(c)(4) concernant les récompenses d'induction pour les nouveaux employés.
Astria Therapeutics (Nasdaq: ATXS), ein biopharmazeutisches Unternehmen, das sich auf allergische und immunologische Erkrankungen spezialisiert hat, hat zwei neuen Mitarbeitern Aktienoptionen im Rahmen seines Inducement Stock Incentive Plans 2022 gewährt. Die Optionen, insgesamt 29.150 Aktien des Stammkapitals, wurden am 1. August 2024 vergeben, mit einem Ausübungspreis von $11,19 pro Aktie, der dem Schlusskurs am Tag der Gewährung entspricht.
Diese Optionen werden über vier Jahre fällig, wobei 25 % nach einem Jahr fällig werden und der Rest in den folgenden 36 Monaten monatlich fällig wird, abhängig von der fortgesetzten Beschäftigung. Diese Gewährung steht im Einklang mit der Nasdaq-Listing-Regel 5635(c)(4) für Anreizvergaben an neue Mitarbeiter.
- Astria Therapeutics is attracting new talent, potentially strengthening its workforce
- The company has a structured equity incentive plan in place for new employees
- The stock option grants may lead to potential dilution for existing shareholders
The options were granted as an inducement material to two employees entering into employment with Astria in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of
About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis. Learn more about our company on our website, www.astriatx.com, or follow us on X and Instagram @AstriaTx and on Facebook and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240802889453/en/
Investor Relations and Media:
Elizabeth Higgins
investors@astriatx.com
Source: Astria Therapeutics, Inc.
FAQ
How many stock options did Astria Therapeutics (ATXS) grant on August 1, 2024?
What is the exercise price of the stock options granted by Astria Therapeutics (ATXS)?
How do the stock options granted by Astria Therapeutics (ATXS) vest?
Under which plan did Astria Therapeutics (ATXS) grant the stock options?
